Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
[Google Scholar] Maroto-Snchez, B., Lopez-Torres, O., Valtuea, J., Benito, P
Not before 2034
Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC
Our Engineering Standard: Inexperienced teams frequently build isolated database schemas that break the moment you try to connect with outside medical vendors
This no-observed-effect level (NOEL) indicates the minimum exposure needed to trigger a detectable physiological or biochemical change
In a recent study posted to the medRxiv* preprint server, researchers developed a personalized therapy selection algorithm for two diabetes type 2 (T2D) treatment drug classes, i.e., sodium-glucose cotransporter 2 (SGLT2)-inhibitors (SGLT2i, reference class) and glucagon-like peptide-1 (GLP1)-receptor agonist (GLP1-RA) medications
US$ 28.48
US$ 23.00
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
US$ 20.85
US$ 26.70
US$ 27.54
